Guest Editors
Prof. Dr. Wei Li
Email: weili06@tongji.edu.cn
Affiliation: Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China
Homepage:
Research Interests: urologic oncology, bladder cancer, renal cancer, tumor microenvironment, precision medicine
Summary
The landscape of urologic oncology is rapidly evolving, driven by advances in targeted therapies, immunotherapy, and a growing emphasis on chronic disease management. Despite these innovations, challenges remain in treatment resistance, long-term toxicity, and optimizing survivorship care. This Special Issue aims to highlight emerging therapeutic strategies—including novel molecular targets, drug delivery systems, and combination regimens—while addressing the critical need for integrated chronic disease management in patients with urologic cancers.
The scope of this issue includes original research, comprehensive reviews, and clinical perspectives on topics such as novel agents in bladder, prostate, and kidney cancers; mechanisms of therapy resistance; biomarkers for treatment response; and models of survivorship and chronic care. Special attention will be given to translational studies bridging molecular insights with clinical applications.
Suggested Themes:
- Novel targeted therapies and immunotherapies in urologic cancers
- Mechanisms of acquired resistance to systemic therapy
- Long non-coding RNAs and other molecular biomarkers in treatment response
- Chronic disease management and survivorship in urologic oncology
- Real-world evidence and patient-reported outcomes
- Emerging technologies (e.g., organoids, liquid biopsy, AI) in treatment personalization
Keywords
urologic oncology, bladder cancer, targeted therapy, immunotherapy, chronic disease management, survivorship, biomarkers, precision medicine, drug resistance, translational research
Login
Register
Submit a Paper
Propose a Special lssue